−15.099 BRL
−706.00 M BRL
1.61 B BRL
124.57 M
About Denali Therapeutics Inc.
Sector
Industry
CEO
Ryan J. Watts
Website
Headquarters
San Francisco
Founded
2013
ISIN
BRD2NLBDR008
FIGI
BBG014XJ88Y9
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Displays a symbol's price movements over previous years to identify recurring trends.